Inclusion Criteria:

- Prior trial of total androgen blockade

- Confirmed biochemical PSA progression on agonist therapy, defined as ≥ 50% increase
in PSA between 2 measurements, taken at least 1 week apart. In patients that are
currently on total androgen blockade (LHRH agonist plus non-steroidal anti-androgen)
there must be a trial withdrawal of androgen receptor antagonists to ensure that
there is no PSA response (6 weeks for bicalutamide and 4 weeks for flutamide or
nilutamide).

- Radiologically confirmed non-metastatic disease within 90 days of registration based
on negative chest radiographs, CT Scan Abdomen/Pelvis and Bone scan

- ECOG ≤ 2

- Age ≥ 18 years

- Serum testosterone of ≤ 50 mg/dl

- PSA ≥ 2.0 ng/ml

- White blood cell count ≥ 3000/mm3

- Platelets ≥ 100,000/mm3

- Serum creatinine ≤ 1.5 x upper limits of normal

- Bilirubin ≤ 1.5 x upper limits of normal

- Alanine transaminase ≤ 1.25 x upper limits of normal

- Estimated life expectancy of at least 12 months

- Able and willing to sign informed consent

Exclusion Criteria:

- Prior treatment with chemotherapy, radiopharmaceuticals, estrogen, PC-SPES,
ketoconazole or other second line hormonal therapy (other than non-steroidal
anti-androgens or Androcur)

- Known allergy to GnRH agonists or antagonists

- Previous treatment with Degarelix

- Major surgery within 4 weeks of registration

- Grade ≥ 3 peripheral neuropathy

- Severe, active co-morbidity such as unstable angina, congestive heart failure or
myocardial infarction within the last 6 months or congenital long QT syndrome

- Acute deep vein thrombosis or pulmonary embolism

- Taking anti-arrhythmia medication

- Second malignancy other than non-melanoma skin cancer unless disease free ≥ 5 years.

- Prior orchiectomy for prostate cancer

- PSA > 100 ng/mL